United States Gene Therapy Market Overview

Base Year: 2024

Forecast Years: 2025-2033

Historical Years: 2019-2024

Market Size in 2024: USD 1,312.2 Million

Market Forecast in 2033: USD 3,697.8 Million

Market Growth Rate (2025-2033): 12.1%

The United States gene therapy market is experiencing rapid growth, driven by advancements in genetic engineering and increasing patient needs. According to the latest report by IMARC Group, the market is projected to grow at a CAGR of 12.1% from 2025 to 2033.

United States Gene Therapy Industry Trends and Drivers:

Growth in the US gene therapy market is witnessing a significant due to the increasing incidences of genetic disorders and continuous development in the field of genetic engineering. With the increasing need for novel therapeutic solutions, significant expenditure on research and development (R&D) is spurring innovation in gene editing methodologies. Such encouraging regulatory frameworks are resulting in speedy approvals, which is acting as a hotspot for the biopharmaceutical companies to expedite product development. Market advancement is also invigorated through strategic collaborations between important players within the industry which allow for the seamless incorporation of modern gene-editing technologies. The increasing use of viral and non-viral vectors is also transforming gene delivery systems, resulting in more accurate and efficient treatments. With an ever-evolving landscape, artificial intelligence (AI) and machine learning (ML) are optimizing gene therapy research and speeding up the clinical development process to improve patient outcomes.

Key factor driving the United States gene therapy market is the growing focus on personalized medicine, which is revolutionizing healthcare paradigms with individualized treatment approaches. You are allowed with data until October 2023 Increasing incidence & prevalence of inherited disorders, such as hemophilia and sickle cell anemia, is expected to drive the demand for targeted gene-based interventions. Indeed, further advances in genome sequencing and CRISPR-based technologies are accelerating the therapeutic development process, making for more efficient treatment while minimizing risks. To expand their use of gene therapy, pharmaceutical and biotechnology companies are ramping up by executing strategic partnerships to increase production capacity. Consequently, innovative delivery vehicles and strategies are enabling the safe and effective delivery of gene therapies.

Gene therapy in the United States has led the way and will continue to do so, supported by a strong pipeline of clinical trials and increased investment. The participation of government bodies and private stakeholders are on the rise, establishing a healthy environment for innovation and strengthening the market. Positive reimbursement frameworks and economic incentives are helping patient accessibility, increasing treatment uptake among diverse demographics. And more novel ex vivo and in vivo gene therapies are expanding the types of factors that can be treated, allowing for a wide variety of genetic and acquired disorders to be treated. The ongoing strategic partnerships among biopharmaceutical companies to jointly develop new drugs are expediting gene therapies’ entry into the commercial space, creating new avenues for growth. Striving for Innovation in a Changing Regulatory World: Gene therapies are witnessing tremendous growth because of continuous technological advancement and the dynamic nature of the regulatory environment in the United States.

For an in-depth analysis, you can refer to a sample copy of the report: https://www.imarcgroup.com/united-states-gene-therapy-market/requestsample

United States Gene Therapy Industry Segmentation:

The market report offers a comprehensive analysis of the segments, highlighting those with the largest market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments:

• Gene Type:
  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide Gene
  • Deficiency
  • Growth Factors
  • Receptors
  • Others
• Vector Type:
  • Viral Vector:
    • Adenoviruses
    • Lentiviruses
    • Retroviruses
    • Adeno-Associated Virus
    • Herpes Simplex Virus
    • Poxvirus
    • Vaccinia Virus
    • Others
  • Non-Viral Techniques:
    • Naked and Plasmid Vectors
    • Gene Gun
    • Electroporation
    • Lipofection
    • Others
• Delivery Method:
  • In-Vivo Gene Therapy
  • Ex-Vivo Gene Therapy
• Application:
  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Others
• Region:
  • Northeast
  • Midwest
  • South
  • West

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key highlights of the report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current, and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA 

Email: [email protected] 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145